Fig. 3
Cumulative incidence of breast cancer recurrence or death by androgen receptor expression (AR poor to moderate [black line]; AR enriched [red line]) for the tamoxifen cohort (A) and the tamoxifen + fluoxymesterone cohort (B)
Fig. 3 | Breast Cancer Research